跳至主要内容
临床试验/NCT04365075
NCT04365075招募中不适用

Excimer Laser Combined With DCB Compared With Angioplasty Alone in the Treatment of Infrapopliteal Lesions in Patients With Critical Limb Ischemia.

Xuanwu Hospital, Beijing1 个研究点 分布在 1 个国家目标入组 184 人开始时间: 2019年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
184
试验地点
1
主要终点
Target lesion revascularization rate

研究概览

简要总结

This study was designed to compare excimer laser combined with drug-coated baloons with angioplasty alone in the treatment of infrapopliteal lesions in patients with critical limb ischemia.

详细描述

This is a randomized study comparing excimer laser combined with drug-coated baloons with angioplasty alone in the treatment of infrapopliteal lesions in patients with critical limb ischemia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The treatment vessel is DeNovo
  • Stenotic (>50%) or occlusive atherosclerotic disease of infrapopliteal artery(s)
  • Reference target vessel diameter between 2-4.0 mm by visual assessment
  • Documented Rutherford Class 4 or 5 symptomatic critical limb ischemia
  • The patient must be >18 years of age
  • Life-expectancy of more than 12 months
  • The patient has no child bearing potential or negative serum pregnancy test
  • within 7 days of the index procedure
  • The patient must be willing and able to return to the appropriate follow-up times for the duration of the study
  • The patient must provide written patient informed consent that is approved by the ethics committee
  • Anatomic Inclusion Criteria:
  • All inflow lesions successfully (<30 residual stenosis) treated prior to target lesion treatment during same procedure or according standard of care without unresolved complications
  • At least one angiographically visible target at the ankle for establishment of straight line flow.

排除标准

  • Patient refusing treatment
  • The target vessel segment diameter is not suitable for available catheter design.
  • Unsuccessfully treated endovascular or bypass( >30% residual stenosis) proximal ( iliac, superficial femoral, popliteal) inflow limiting arterial/graft stenosis
  • Lesion lies within or adjacent to an aneurysm
  • The patient has a known allergy to heparin, Aspirin or other antiaggregant therapies or a bleeding diatheses or is unable, or unwilling, to tolerate such therapies.
  • The patient has a history of prior life-threatening contrast media reaction.
  • The patient is currently enrolled in another investigational device or drug trial.
  • The patient is currently breast-feeding, pregnant or intends to become pregnant.
  • The patient is unable to provide informed consent
  • The patient has end stage renal disease (currently on any form of dialysis)
  • Known Left Ventricular Ejection Fraction < 35%
  • The patient has had a myocardial ischemia within 30 days prior to enrollment
  • The patient has had a cardiovascular accident within 90 days prior to enrollment
  • Serum Creatinine > 150 µmol
  • The patient has a previous bypass in the target limb
  • The patient has a current systemic infection

结局指标

主要结局

Target lesion revascularization rate

时间窗: 6-months

Free target vascular occlusion and clinically driven target lesion revascularization rate confirmed by ultrasound examination.

次要结局

  • Length of hospital stay(6-months)
  • hospitalization costs(6-months)
  • Incidence of major adverse events(6-months)
  • Major amputation rate(6-months)
  • Mortality(6-months)
  • Ankle Brachial Index(6-months)
  • transcutaneous oxygen pressure(6-months)
  • Wound healing wagner score (for patients with Rutherford classification 5)(6-months)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验